Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Income towards Parent Company (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Income towards Parent Company for 14 consecutive years, with -$29.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company rose 27.16% year-over-year to -$29.8 million, compared with a TTM value of -$133.8 million through Dec 2025, down 48.07%, and an annual FY2025 reading of -$3.7 million, down 15995.65% over the prior year.
  • Income towards Parent Company was -$29.8 million for Q4 2025 at Karyopharm Therapeutics, down from -$25.7 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $38.7 million in Q4 2021 and bottomed at -$57.4 million in Q1 2021.
  • Average Income towards Parent Company over 5 years is -$32.8 million, with a median of -$36.8 million recorded in 2022.
  • The sharpest move saw Income towards Parent Company skyrocketed 711.4% in 2021, then plummeted 247.12% in 2025.
  • Year by year, Income towards Parent Company stood at $38.7 million in 2021, then tumbled by 199.53% to -$38.5 million in 2022, then fell by 9.14% to -$42.1 million in 2023, then grew by 2.77% to -$40.9 million in 2024, then rose by 27.16% to -$29.8 million in 2025.
  • Business Quant data shows Income towards Parent Company for KPTI at -$29.8 million in Q4 2025, -$25.7 million in Q3 2025, and -$35.0 million in Q2 2025.